Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: results of 10 years of use
https://doi.org/10.21518/2079-701X-2022-16-21-139-145
Abstract
The article presents a review of the basic data on the efficacy and safety of the drug tofacitinib, the place of the drug in the treatment of rheumatoid arthritis (RA) patients according to current international and Russian recommendations. Data on the mechanism of action of Janus kinase inhibitors, the spectrum of cytokines inhibited by tofacitinib is presented. The results of major randomised controlled trials demonstrating high clinical efficacy in patients who have not responded to methotrexate (MT) and other synthetic classical anti-rheumatic drugs (SCARDs), genetically engineered biologic drugs, are presented, with equal efficacy of tofacitinib when given as monotherapy or in combination with MT or other SCARDs, with adalimumab. The safety of tofacitinib with long-term treatment (up to 9.5 years) is analysed. The cardiovascular tolerability of tofacitinib is presented separately, considering the proposals discussed at the last EULAR 2022 Congress. The low incidence of serious cardiovascular adverse events, including venous thrombosis and thromboembolism over the long-term follow-up period, and the risk of these adverse events, which was no higher than on the selective Janus kinase inhibitor baricitinib, are presented. Changes in laboratory parameters (haemoglobin, neutrophil count, aminotransferase concentration) during tofacitinib administration are described. Domestic data on the use of tofacitinib in the treatment of RA patients is demonstrated. An association was shown between early clinical response to tofacitinib (5 mg twice daily) and a reduction in RA activity after 3 and 6 months in RA patients. Tofacitinib in real clinical practice showed early development of effect (by week 12) in the group of patients who did not respond to MT and in 60% of cases to genetically engineered biologic drugs, with respect to indicators of inflammatory activity of RA and functional status of patients. Domestic authors have noted the high safety of tofacitinib. A domestic generic version of the original drug tofacitinib has been reported to be registered for the same indications: RA, psoriatic arthritis, plaque psoriasis, ulcerative colitis.
About the Authors
N. V. Chichasova
Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Natalia V. Chichasova, Dr. Sci. (Med.), Senior Lecturer of the Educational and Methodological Department; Professor of the Department of Rheumatology
34А, Kashirskoe Shosse, Moscow, 115522
2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993
A. M. Lila
Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Aleksander M. Lila, Dr. Sci. (Med.), Director; Head of the Department of Rheumatology
34А, Kashirskoe Shosse, Moscow, 115522
2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993
References
1. Schwartz D.M., Bonelli M., Gadina M., O’Shea J.J. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36. https://doi.org/10.1038/nrrheum.2015.167.
2. Насонов Е.Л. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409–419. https://doi.org/10.14412/1995-4484-2017-409-419. Nasonov E.L. Pharmacotherapy for rheumatoid arthritis: new strategy, new targets. Rheumatology Science and Practice. 2017;55(4):409–419. (In Russ.) https://doi.org/10.14412/1995-4484-2017-409-419.
3. Smolen J.S., Aletaha D., Bijlsma J.W., Breedveld F.C., Boumpas D., Burmester G. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–637. https://doi.org/10.1136/ard.2009.123919.
4. Van Vollenhoven R.F., Mosca M., Bertsias G., Isenberg D., Kuhn A., Lerstrom K. et al. Treat-to target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958–967. https://doi.org/10.1136/annrheumdis-2013-205139.
5. Smolen J., Braun J., Dougados M., Emery P., Fitzgerald O., Helliwell P. et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6–16. https://doi.org/10.1136/annrheumdis-2013-203419.
6. Kitz U., Smolen J., Bardin T., Cohen S.A., Dalbeth N., Doherty M. et al. Treat-totarget (T2T) recommendations for gout. Ann Rheum Dis. 2017;76(4):632–638. https://doi.org/10.1136/annrheumdis-2016-209467.
7. Smolen J.S., Landewé R.B.M., Bijlsma J.W.J., Burmester G.R., Dougados M., Kerschbaumer A. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. https://doi.org/10.1136/annrheumdis-2019-216655.
8. Dhillon S. Tofacitinib: A Review in Rheumatoid Arthritis. Drugs. 2017;77(18):1987–2001. https://doi.org/10.1007/s40265-017-0835-9.
9. Berekmeri A., Mahmood F., Wittmann M., Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719–730. https://doi.org/10.1080/1744666X.2018.
10. Ly K., Beck K.M., Smith M.P., Orbai A.M., Liao W. Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. Psoriasis (Auckl). 2019;9:97–107. https://doi.org/10.2147/PTT.S161453.
11. D’Amico F., Parigi T.L., Fiorino G., Peyrin-Biroulet L., Danese S. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to realworld experience. Ther Adv Gastroenterol. 2019;16(12):1756284819848631. https://doi.org/10.1177/1756284819848631.
12. Smolen J.S., van der Heijde D., Machold K.P., Aletaha D., Landewe R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73(1):3–5. https://doi.org/10.1136/annrheumdis-2013-204317.
13. Насонов Е.Л. (ред.). Российские клинические рекомендации. Ревматология. М.: ГЭОТАР-Медиа; 2017. 456 с. Nasonov E.L. (ed.). Russian clinical guidelines. Rheumatology. Moscow: GEOTAR-Media; 2017. 456 p. (In Russ.)
14. Singh J.A., Guyatt G., Ogdie A., Gladman D.D., Deal C., Deodhar A. et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2019;71(1):2–29. https://doi.org/10.1002/acr.23789.
15. Hodge J.A., Kawabata T.T., Krishnaswami S., Clark J.D., Telliez J.B., Dowty M.E. et al. The mechanism of action of tofacitinib – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318–328. Available at: https://pubmed.ncbi.nlm.nih.gov/26966791/.
16. Ghoreschi K., Jesson M.I., Li X., Lee J.L., Ghosh S., Alsup J.W. et al. Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234–4243. https://doi.org/10.4049/jimmunol.1003668.
17. Lee E.B., Fleischmann R., Hall S., Wilkinson B., Bradley J.D., Gruben D. et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377–2386. https://doi.org/10.1056/nejmoa1310476.
18. Burmester G.R., Blanco R., Charles-Schoeman C., Vollenhaupt J., Zerbini C., Benda B. et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451–460. https://doi.org/10.1016/s0140-6736(12)61424-x.
19. Van Vollenhoven R.F., Fleischmann R., Cohen S., Lee E.B., García Meijide J.A., Wagner S. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–519. https://doi.org/10.1056/NEJMoa1112072.
20. Fleischmann R., Kremer J., Cush J., Schulze-Koops H., Connel C.A., Bradley J.D. et al. Placebo-controlled trial of Tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495–507. https://doi.org/10.1056/NEJMoa1109071.
21. Kremer J.M., Li Z.G., Hall S., Fleischmann R., Genovese M., Martin-Mola E. et al. Tofacitinib in combination with nonbilogic disease modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trials. Ann Int Med. 2013;159(4):253–261. https://doi.org/10.7326/0003-4819-159-4-201308200-00006.
22. Fleischmann R., Kremer J., Cush J., Schulze-Koops H., Connell C.A., Bradley J.D. et al. Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. N Engl J Med. 2012;367(6):495–507. https://doi.org/10.1056/NEJMoa1109071.
23. Conaghan P.G., Østergaard M., Bowes M.A., Wu C., Fuerst T., van der Heijde D. et al. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis. 2016;75(6):1024–1033. https://doi.org/10.1136/annrheumdis-2015-208267.
24. Fleischmann R.M., Huizinga T.W.J., Kavanauch A.F., Wilkinson B., Kwok K., DeMasi R., van Vollenchoven R.F. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open. 2016;2(2):e000262. https://doi.org/10.1136/rmdopen-2016-000262.
25. Van der Hijde D., Tanaka Y., Fleischmann R., Keystone E., Kremer J., Zerbini C. et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559–570. https://doi.org/10.1002/art.37816.
26. Landeve R.B.M., Connell C.A., Bradley J.D., Wilkinson B., Gruben D., Strengholt S. van der Heijde D. Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials. Arthritis Res Ther. 2016;18(1):212. https://doi.org/10.1186/s13075-016-1106-y.
27. Wollenhaupt J., Silverfield J., Lee E.B., Curtis J.R., Wood S.P., Soma K. et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open label, long term extension studies. J Rheumatol. 2014;41(5):837–852. https://doi.org/10.3899/jrheum.130683.
28. Yamanaka H., Tanaka Y., Takeuchi T., Sugiyama N., Yuasa H., Toyoizumi S. et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background MTX, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016;18:34. https://doi.org/10.1186/s13075-016-0932-2.
29. Cohen S.B., Tanaka Y., Mariette X., Curtis J.R., Lee E.B., Nash P. et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76(7):1253–1262. https://doi.org/10.1136/annrheumdis2016-210457.
30. Wollenhaupt J., Lee E.B., Curtis J.R., Silverfield J., Terry K., Soma K. et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):89. https://doi.org/10.1186/s13075-019-1866-2.
31. Pope J.E., Keystone E., Jamal S., Wang L., Fallon L., Woolcott J. et al. Persistence of tofacitinib in the treatment of rheumatoid arthritis in open-label, long-term extension studies up to 9.5 years. ACR Open Rheumatol. 2019;1(2):73–82. https://doi.org/10.1002/acr2/1010.
32. Wollenhaupt J., Lee E.B., Curtis J.R., Silverfield J., Terry K., Soma K. et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):89. https://doi.org/10.1186/s13075-019-1866-2.
33. Wintrop K.L., Yamanaka H., Valdez H., Mortensen E., Chew R., Krishnaswami S. et al. Herpes Zoster and Tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(10):2675–2684. https://doi.org/10.1002/art38745.
34. Yttberg S.R., Bhatt D.L., Mikuls T.R., Koch G.G., Fleischmann R., Rivas J.L. et al. Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–326. https://doi.org/10.1056/NEJMoa2109927.
35. Xie W., Huang Y., Xiao S., Sun X., Fan Y., Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019;78(8):1048–1054. https://doi.org/10.1136/annrheumdis-2018-214846.
36. Charles-Schoeman C., DeMasi R., Valdez H., Soma K., Hwang L.J., Boy M.G. et al. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis. Arthritis Rheum. 2019;71(9):1450–1459. https://doi.org/10.1002/art.40911.
37. Kume K., Amano K., Yamada S., Kanazava T., Ohta H., Hatta K. et al. Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study. Rheumatol Int. 2017;37(12):2079–2085. https://doi.org/10.1007/s00296-017-3844-9.
38. Luisse A., Pierini F., Gandino I., Botta E., Brites F., Boero L. et al. Effect of tofacitinib on the qualityve profile of high density lipoproteins molecules in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71(Suppl. 10):1415. Available at: https://acrabstracts.org/abstract/effect-of-tofacitinib-on-thequalitative-profile-of-high-density-lipoproteins-molecules-in-patients-withrheumatoid-arthritis/.
39. Vallejo-Yagüe E., Weiler S., Micheroli R., Burden A.M. Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase. Drug Saf. 2020;43(9):881–891. https://doi.org/10.1007/s40264-020-00958-9.
40. Mosevoll K.A., Johansen S., Wendelbo Ø., Nepstad I., Bruserud Ø., Reikvam H. Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis. Front Med (Lausanne). 2018;5:147. https://doi.org/10.3389/fmed.2018.00147.
41. Giménez Poderós T., Gallardo Borge S., Vazquez-Ferreiro P. Risk of Venous Thromboembolism Associated With Tofacitinib and Baricitinib: A Systematic Review and Indirect Meta-Analysis. Pharmacotherapy. 2020;40(12):1248–1264. https://doi.org/10.1002/phar.2472.
42. Schulze-Koops H., Strand V., Nduaka C., DeMasi R., Wallenstein G., Kwok K., Wang L. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology (Oxford). 2017;56(1):46–57. https://doi.org/10.1093/rheumatology/kew329.
43. Каратеев А.Е., Погожева Е.Ю., Амирджанова В.Н., Филатова Е.С., Лила А.М., Мазуров В.И. и др. Оценка эффективности тофацитиниба при ревматоидном артрите в реальной клинической практике: взаимосвязь между снижением боли в первые 4 недели и активностью заболевания через 3–6 месяцев. Научно-практическая ревматология. 2021;59(4):394–400. https://doi.org/10.47360/1995-4484-2021-394-400. Karateev A.E., Pogozheva E.Yu., Amirjanova V.N., Filatova E.S., Lila A.M., Mazurov V.I. et al. Evaluation of the effectiveness of Tofacitinib in rheumatoid arthritis in real clinical practice: The relationship between pain relief in the first 4 weeks and disease activity after 3–6 months. Rheumatology Science and Practice. 2021;59(4):394–400. (In Russ.) https://doi.org/10.47360/1995-4484-2021-394-400.
44. Авдеева А.С., Мисиюк А.С., Сатыбалдыев А.М., Лукина Г.В., Сороцкая В.Н., Жиляев Е.В. и др. Анализ результатов терапии тофацитинибом в реальной клинической практике (по данным Общероссийского регистра больных артритом ОРЕЛ). Научно-практическая ревматология. 2020;58(3):262–267. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/2891. Avdeeva A.S., Misiyuk A.S., Satybaldyev A.M., Lukina G.V., Sorotskaya V.N., Zhilyaev E.V. et al. Analysis of the results of tofacitinib therapy in real clinical practice according to the All-Russian arthritis registry (OREL). Rheumatology Science and Practice. 2020;58(3):262–267. (In Russ.) Available at: https://rsp.mediar-press.net/rsp/article/view/2891.
45. Мазуров В.И., Трофимов Е.А., Самигуллина Р.Р., Гайдукова И.З. Место тофацитиниба в стратегии лечения ревматоидного артрита. Научнопрактическая ревматология. 2018;56(2):152–156. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/2519. Mazurov V.I., Trofimov E.A., Samigullina R.R., Gaidukova I.Z. The place of tofacitinib in the treatment strategy of rheumatoid arthritis. Rheumatology Science and Practice. 2018;56(2):152–156. (In Russ.) Available at: https://rsp.mediar-press.net/rsp/article/view/2519.
Review
For citations:
Chichasova NV, Lila AM. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: results of 10 years of use. Meditsinskiy sovet = Medical Council. 2022;(21):139-145. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-21-139-145
Views:
491
Email this article 